Stock BMY BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Bristol-Myers Squibb Company Share Price

Equities

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse
Other stock markets
 21:00:02 26/04/2024 BST 		5-day change 1st Jan Change
44.85 USD +0.34% Intraday chart for Bristol-Myers Squibb Company -8.34% -12.59%
04-26 S&P 500 Q1 earnings estimated growth improves; stocks up for week RE
04-26 Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51 MT

Financials

Sales 2024 * 45.97B 3,680B Sales 2025 * 46.24B 3,702B Capitalization 90.92B 7,278B
Net income 2024 * -4.22B -338B Net income 2025 * 10.4B 833B EV / Sales 2024 * 2.81 x
Net Debt 2024 * 38.34B 3,069B Net Debt 2025 * 30.78B 2,464B EV / Sales 2025 * 2.63 x
P/E ratio 2024 *
-18.4 x
P/E ratio 2025 *
8.14 x
Employees 34,100
Yield 2024 *
5.36%
Yield 2025 *
5.66%
Free-Float 69.26%
More Fundamentals * Assessed data

Chart Bristol-Myers Squibb Company

Dynamic Chart

Latest news about Bristol-Myers Squibb Company

S&P 500 Q1 earnings estimated growth improves; stocks up for week RE
Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51 MT
UBS Cuts Bristol-Myers Squibb Price Target to $47 From $52, Maintains Neutral Rating MT
Barclays Adjusts Price Target on Bristol-Myers Squibb to $43 From $51 MT
JPMorgan Adjusts Bristol-Myers Squibb's Price Target to $60 From $65 MT
Bristol-Myers Squibb Says European Regulator Recommends Approval of Bladder Cancer Combination Therapy MT
Bristol Myers: positive opinion from the CHMP for Opdivo CF
Bristol Myers Gets CHMP Backing for Opdivo Combo in Bladder Cancer DJ
Morgan Stanley Adjusts Price Target on Bristol-Myers Squibb Company to $37 From $40 MT
Truist Cuts Price Target on Bristol-Myers Squibb to $64 From $68, Keeps Buy Rating MT
BMO Capital Adjusts Price Target on Bristol-Myers Squibb Company to $48 From $55 MT
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma CI
Health Care Drops Amid Mixed Earnings -- Health Care Roundup DJ
Sector Update: Health Care Stocks Decline Late Afternoon MT
Sector Update: Health Care Stocks Drop in Afternoon Trading MT
More news

Latest transcript on Bristol-Myers Squibb Company

Logo Bristol-Myers Squibb Company
Bristol-Myers Squibb Company, Q1 2024 Earnings Call, Apr 25, 2024
More transcripts

Analyst Recommendations on Bristol-Myers Squibb Company

Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51 MT
UBS Cuts Bristol-Myers Squibb Price Target to $47 From $52, Maintains Neutral Rating MT
Barclays Adjusts Price Target on Bristol-Myers Squibb to $43 From $51 MT
JPMorgan Adjusts Bristol-Myers Squibb's Price Target to $60 From $65 MT
Morgan Stanley Adjusts Price Target on Bristol-Myers Squibb Company to $37 From $40 MT
More recommendations

Press releases Bristol-Myers Squibb Company

CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma BU
Bristol Myers Squibb : Q1 2024 Results Presentation (with Appendix) PU
Bristol Myers: Q1 Earnings Snapshot AQ
Bristol Myers Squibb Reports First Quarter Financial Results for 2024 BU
Bristol Myers Squibb : Preliminary Q1 2024 Acquired IPRD and Licensing Income Schedule PU
More press releases

News in other languages on Bristol-Myers Squibb Company

Bristol Myers : avis favorable du CMHP pour Opdivo
STATI UNITI. - I titoli da tenere d'occhio a Wall Street (aggiornamento)
EE.UU. - Valores a seguir en Wall Street (actualizado)
Bristol Myers : lourde perte trimestrielle sur des charges
Borsa Usa, futures incerti, Meta Platforms pesa su megacap
More news

Quotes and Performance

1 day+0.34%
1 week-8.34%
Current month-17.30%
1 month-14.65%
3 months-9.76%
6 months-15.33%
Current year-12.59%
More quotes

Highs and lows

1 week
44.34
Extreme 44.34
49.56
1 month
44.34
Extreme 44.34
54.48
Current year
44.34
Extreme 44.34
55.04
1 year
44.34
Extreme 44.34
69.10
3 years
44.34
Extreme 44.34
81.44
5 years
42.48
Extreme 42.48
81.44
10 years
42.48
Extreme 42.48
81.44
More quotes

Managers and Directors - Bristol-Myers Squibb Company

Managers TitleAgeSince
Christopher Boerner CEO
 Chief Executive Officer 53 31/01/15
David Elkins DFI
 Director of Finance/CFO 55 19/11/19
Greg Meyers CTO
 Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Phyllis Yale BRD
 Director/Board Member 66 19/11/19
Peter Arduini BRD
 Director/Board Member 59 31/03/16
Derica Rice BRD
 Director/Board Member 59 31/08/20
More insiders

ETFs positioned on Bristol-Myers Squibb Company

Name Weight AuM 1st Jan change Investor Rating
AGF U.S. MARKET NEUTRAL ANTI-BETA FUND - USD ETF AGF U.S. Market Neutral Anti-Beta Fund - USD
12.97% 215 M€ +10.68% -
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD ETF BMO MSCI Genomic Innovation Index ETF - CAD
4.99% 2 M€ -.--%
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY ETF Nomura NEXT FUNDS International Equity MSCI-KOKUSAI (Yen-Hedged) ETF - JPY
4.01% 18 M€ +3.79% -
More ETFs positioned on Bristol-Myers Squibb Company

Quotes

Date Price Change Volume
26/04/24 44.85 +0.34% 21,281,927
25/04/24 44.7 -8.51% 45,069,042
24/04/24 48.86 -0.27% 16,057,141
23/04/24 48.99 -0.31% 9,153,290
22/04/24 49.14 +0.43% 7,929,534

Delayed Quote Nyse, April 26, 2024 at 09:00 pm

More quotes

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.
Sector
Pharmaceuticals
Calendar
07/05/2024 - Annual General Meeting
Related indices
S&P 500
More about the company

Income Statement Evolution

More financial data

Ratings for Bristol-Myers Squibb Company

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
27
Last Close Price
44.85 USD
Average target price
54.02 USD
Spread / Average Target
+20.45%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
BRISTOL-MYERS SQUIBB COMPANY Stock Bristol-Myers Squibb Company
-12.59% 90.92B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BMY Stock